EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structure-Guided Design of N-Methylpropargylamino-Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer’s Disease

Barbora Svobodova, Lenka Pulkrabkova, Dawid Panek, Anna Misiachna, Marharyta Kolcheva, Rudolf Andrys, Jiri Handl, Jan Capek iD, Pavlina Nyvltova, Tomas Rousar, Lukas Prchal, Vendula Hepnarova und 8 weitere

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24119124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Barbora Svobodova und 19 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. Hauptthemen laut MEDLINE: Alzheimer Disease, Neuroblastoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Czech Science Foundation, Next Generation EU, Long term development plan (Faculty of Military Health Sciences) Medical issues of WMD II.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is a complex disease with an unknown etiology. Available treatments, limited to cholinesterase inhibitors and N-methyl-d-aspartate receptor (NMDAR) antagonists, provide symptomatic relief only. As single-target therapies have not proven effective, rational specific-targeted combination into a single molecule represents a more promising approach for treating AD, and is expected to yield greater benefits in alleviating symptoms and slowing disease progression. In the present study, we designed, synthesized, and biologically evaluated 24 novel N-methylpropargylamino-quinazoline derivatives. Initially, compounds were thoroughly inspected by in silico techniques determining their oral and CNS availabilities. We tested, in vitro, the compounds’ effects on cholinesterases and monoamine oxidase A/B (MAO-A/B), as well as their impacts on NMDAR antagonism, dehydrogenase activity, and glutathione levels. In addition, we inspected selected compounds for their cytotoxicity on undifferentiated and differentiated neuroblastoma SH-SY5Y cells. We collectively highlighted II-6h as the best candidate endowed with a selective MAO-B inhibition profile, NMDAR antagonism, an acceptable cytotoxicity profile, and the potential to permeate through BBB. The structure-guided drug design strategy applied in this study imposed a novel concept for rational drug discovery and enhances our understanding on the development of novel therapeutic agents for treating AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseNeuroblastomaHumansMonoamine Oxidase InhibitorsCholinesterase InhibitorsMonoamine OxidaseDrug DesignAcetylcholinesteraseStructure-Activity Relationship

Stichwörter der Autor:innen

Alzheimer’s diseaseN-methyl-d-aspartate receptoracetylcholinesteraseenzyme inhibitionmonoamine oxidase A/Bmulti-target directed ligands

Substanzen

Monoamine Oxidase InhibitorsCholinesterase InhibitorsMonoamine OxidaseAcetylcholinesterase

Autor:innen und Institutionen

  • Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic.
  • Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic.
  • Department of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.
  • Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic.
  • Department of Physiology, Faculty of Science, Charles University in Prague, Albertov 6, 128 43 Prague, Czech Republic.
  • Department of Chemistry, Faculty of Science, University Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic.

ORCID-Profile: Jan Capek, Lubica Muckova, Vladimir Finger, Jan Korabecny

Förderung

  • Czech Science Foundation
  • Next Generation EU
  • Long term development plan (Faculty of Military Health Sciences) Medical issues of WMD II
  • Ministry of Defence of the Czech Republic—DRO of the University of Defence, Faculty of Military Health Sciences Hradec Kralove, Czech Republic—Medical issues o…

Zitieren

APA

Svobodova, B., Pulkrabkova, L., Panek, D., Misiachna, A., Kolcheva, M., Andrys, R., Handl, J., Capek, J., Nyvltova, P., Rousar, T., Prchal, L., Hepnarova, V., Hrabinova, M., Muckova, L., Tosnerova, D., Karabanovich, G., Finger, V., Soukup, O., Horak, M., & Korabecny, J. (2023). Structure-Guided Design of N-Methylpropargylamino-Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24119124

Vancouver

Svobodova B, Pulkrabkova L, Panek D, Misiachna A, Kolcheva M, Andrys R, et al. Structure-Guided Design of N-Methylpropargylamino-Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer’s Disease. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24119124

BibTeX
@article{Svobodova2023,
  author = {Svobodova, Barbora and Pulkrabkova, Lenka and Panek, Dawid and Misiachna, Anna and Kolcheva, Marharyta and Andrys, Rudolf and Handl, Jiri and Capek, Jan and Nyvltova, Pavlina and Rousar, Tomas and Prchal, Lukas and Hepnarova, Vendula and Hrabinova, Martina and Muckova, Lubica and Tosnerova, Daniela and Karabanovich, Galina and Finger, Vladimir and Soukup, Ondrej and Horak, Martin and Korabecny, Jan},
  title = {Structure-Guided Design of N-Methylpropargylamino-Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer’s Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24119124}
}
Kostenlos starten →